$LQDA

SINGH RAMAN sold $1.8M of LQDA

SINGH RAMAN sold 29,494 shares of Liquidia Corp (LQDA) at $60.13 ($1.77M total) on 2026-05-21.

Original reporting
SEC EDGAR · SINGH RAMAN
Published May 26, 2026, 10:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishMed
01

Why it matters

The disclosure may influence short-term trading sentiment, but it does not introduce new company-specific catalysts (no earnings, trial, deal, or regulatory action mentioned).

02

Market read

Traders may monitor LQDA for follow-through selling/insider activity, but fundamentals are unchanged based on this filing alone.

03

What to watch

The sale is not explicitly tied to a 10b5-1 plan; without context on prior grants/vesting or total holdings history, directional inference is weak.

Relevance 8/10Timing: Immediate (today’s SEC Form 4 filing may affect intraday sentiment/flow).

Background

The article is a SEC Form 4 insider transaction disclosure for Liquidia Corp, filed on 2026-05-26.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Liquidia director Singh Raman filed an open-market sale of 29,494 shares (~$1.77M) on 2026-05-21 via SEC Form 4.

Expected impact

Likely modest, short-lived downside/volatility around the filing; no strong directional signal without follow-on news.

Evidence & confidence

This is a routine Form 4 disclosure with no stated reason, no 10b5-1 plan, and no accompanying operational/clinical update in the article.

Market effects

Limited read-across; insider sales are company-specific unless paired with broader sector catalysts.

None indicated; this is a US-listed issuer’s insider transaction.

None indicated.

Counterpoint

Director selling can be driven by diversification, tax planning, or personal liquidity needs rather than bearish expectations.

Key entities

  • Liquidia Corp

    Subject of the SEC Form 4 insider sale by a director (Singh Raman).

  • Singh Raman

    Director who sold 29,494 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient